AI Summary & Key Takeaways
AI InsightResults of this study suggests that doxorubicin increases erythrocyte osmotic fragility and boron containing molecules are not sufficient to recover this untoward effect on erythrocytes at the applied dosage.Conclusion: Possible mechanisms of this result and testing in a dose dependent manner can be tested in future studies.
📌 3 Key Takeaways
Abstract
Objective: Doxorubicin is a potent antineoplastic agent used in chemical treatment of cancer. However due to their cardiotoxic effects, its use is limited and currently subject for extensive research. Cardiomyopathy caused by doxorubicin still remains as a major concern for this potent drug. This study was aimed to contribute to this issue which needs novel preventive treatment for this side effect.Materials and Methods: Boron and boron containing molecules are subject of medical research due to their properties such as antioxidant nature. They are tested in various diseases and experimental setups. In this study Boric acid, Potassium tetraborate, Amonium biborat tetrahidrat was given to male rats at 10 mg/kg/day for 6 weeks. All study groups (n=8 each) received Doxorubicin and Boron containing compounds via intraperitoneal route. Following 6 weeks blood was withdrawn and erythrocyte osmotic fragility test was applied. Results: Erythrocyte fragility values of all doxorubicin containing groups increases and become significant at 0.5, 0.6, 0.7 and 0.8% NaCl concentrations (p<0.05). Among doxorubicin groups no significant difference was observed. Results of this study suggests that doxorubicin increases erythrocyte osmotic fragility and boron containing molecules are not sufficient to recover this untoward effect on erythrocytes at the applied dosage.Conclusion: Possible mechanisms of this result and testing in a dose dependent manner can be tested in future studies.